Logo image of PMVP

PMV PHARMACEUTICALS INC (PMVP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PMVP - US69353Y1038 - Common Stock

1.205 USD
-0.03 (-2.82%)
Last: 1/8/2026, 10:21:06 AM
Fundamental Rating

2

Taking everything into account, PMVP scores 2 out of 10 in our fundamental rating. PMVP was compared to 530 industry peers in the Biotechnology industry. While PMVP has a great health rating, there are worries on its profitability. PMVP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PMVP had negative earnings in the past year.
PMVP had a negative operating cash flow in the past year.
PMVP had negative earnings in each of the past 5 years.
In the past 5 years PMVP always reported negative operating cash flow.
PMVP Yearly Net Income VS EBIT VS OCF VS FCFPMVP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

PMVP has a Return On Assets of -61.79%. This is comparable to the rest of the industry: PMVP outperforms 41.51% of its industry peers.
PMVP's Return On Equity of -68.35% is in line compared to the rest of the industry. PMVP outperforms 56.42% of its industry peers.
Industry RankSector Rank
ROA -61.79%
ROE -68.35%
ROIC N/A
ROA(3y)-28.39%
ROA(5y)-22.41%
ROE(3y)-31.23%
ROE(5y)-24.41%
ROIC(3y)N/A
ROIC(5y)N/A
PMVP Yearly ROA, ROE, ROICPMVP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PMVP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMVP Yearly Profit, Operating, Gross MarginsPMVP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for PMVP has been increased compared to 1 year ago.
Compared to 5 years ago, PMVP has more shares outstanding
There is no outstanding debt for PMVP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PMVP Yearly Shares OutstandingPMVP Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PMVP Yearly Total Debt VS Total AssetsPMVP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

PMVP has an Altman-Z score of -2.61. This is a bad value and indicates that PMVP is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.61, PMVP perfoms like the industry average, outperforming 46.42% of the companies in the same industry.
There is no outstanding debt for PMVP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.61
ROIC/WACCN/A
WACCN/A
PMVP Yearly LT Debt VS Equity VS FCFPMVP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 10.76 indicates that PMVP has no problem at all paying its short term obligations.
The Current ratio of PMVP (10.76) is better than 84.91% of its industry peers.
PMVP has a Quick Ratio of 10.76. This indicates that PMVP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.76, PMVP belongs to the top of the industry, outperforming 84.91% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.76
Quick Ratio 10.76
PMVP Yearly Current Assets VS Current LiabilitesPMVP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

PMVP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.00%.
EPS 1Y (TTM)-60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PMVP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.28% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-38.24%
EPS Next 2Y-13.21%
EPS Next 3Y1.55%
EPS Next 5Y5.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMVP Yearly Revenue VS EstimatesPMVP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
PMVP Yearly EPS VS EstimatesPMVP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PMVP. In the last year negative earnings were reported.
Also next year PMVP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PMVP Price Earnings VS Forward Price EarningsPMVP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMVP Per share dataPMVP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.21%
EPS Next 3Y1.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PMVP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PMV PHARMACEUTICALS INC

NASDAQ:PMVP (1/8/2026, 10:21:06 AM)

1.205

-0.03 (-2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners60.53%
Inst Owner Change0%
Ins Owners3.3%
Ins Owner Change1.66%
Market Cap64.12M
Revenue(TTM)N/A
Net Income(TTM)-82.70M
Analysts85
Price Target7.75 (543.15%)
Short Float %3.39%
Short Ratio4.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.15%
Min EPS beat(2)-4.86%
Max EPS beat(2)2.57%
EPS beat(4)2
Avg EPS beat(4)-1.81%
Min EPS beat(4)-15.92%
Max EPS beat(4)10.97%
EPS beat(8)5
Avg EPS beat(8)15.44%
EPS beat(12)9
Avg EPS beat(12)15.36%
EPS beat(16)12
Avg EPS beat(16)11.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5%
PT rev (3m)-17.84%
EPS NQ rev (1m)-0.62%
EPS NQ rev (3m)3.57%
EPS NY rev (1m)-0.16%
EPS NY rev (3m)0.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-1.6
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0
BVpS2.27
TBVpS2.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.79%
ROE -68.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.39%
ROA(5y)-22.41%
ROE(3y)-31.23%
ROE(5y)-24.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.36%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.76
Quick Ratio 10.76
Altman-Z -2.61
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)875.85%
Cap/Depr(5y)621.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.11%
EPS Next Y-38.24%
EPS Next 2Y-13.21%
EPS Next 3Y1.55%
EPS Next 5Y5.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.34%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.04%
OCF growth 3YN/A
OCF growth 5YN/A

PMV PHARMACEUTICALS INC / PMVP FAQ

What is the fundamental rating for PMVP stock?

ChartMill assigns a fundamental rating of 2 / 10 to PMVP.


Can you provide the valuation status for PMV PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to PMV PHARMACEUTICALS INC (PMVP). This can be considered as Overvalued.


How profitable is PMV PHARMACEUTICALS INC (PMVP) stock?

PMV PHARMACEUTICALS INC (PMVP) has a profitability rating of 1 / 10.


What is the earnings growth outlook for PMV PHARMACEUTICALS INC?

The Earnings per Share (EPS) of PMV PHARMACEUTICALS INC (PMVP) is expected to decline by -38.24% in the next year.